Presentation is loading. Please wait.

Presentation is loading. Please wait.

Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment- resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma  Shumaila.

Similar presentations


Presentation on theme: "Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment- resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma  Shumaila."— Presentation transcript:

1 Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment- resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma  Shumaila Muhammad Iqbal, Kathryn Stecklein, Joseph Sarow, Michael Krabak, Jens Hillengass, Philip McCarthy  Clinical Lymphoma, Myeloma and Leukemia  Volume 19, Issue 1, Pages e33-e36 (January 2019) DOI: /j.clml Copyright © 2018 Elsevier Inc. Terms and Conditions

2 Figure 1 Total Urine Protein (mg/24-Hour)
Abbreviations: AutoPBSCT = autologous peripheral blood stem cell transplantation; ERD = elotuzumab, lenalidomide, and dexamethasone; FLC = free light chain. Clinical Lymphoma, Myeloma and Leukemia  , e33-e36DOI: ( /j.clml ) Copyright © 2018 Elsevier Inc. Terms and Conditions


Download ppt "Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment- resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma  Shumaila."

Similar presentations


Ads by Google